We are thrilled to be working with the NIH RADx Next team to accelerate our groundbreaking SARS-CoV-2 nanosensor antigen test.  

 

The RADx initiative provides world-class clinical, technical, commercialization, regulatory support, and expert one-on-one guidance to project teams, in addition to funding for solutions like Pinpoint Science’s SARS-CoV-2 Nanosensor antigen test.